Current Hypertension Reports

, Volume 13, Issue 6, pp 436–441 | Cite as

Heart Failure Associated with Sunitinib: Lessons Learned from Animal Models

Mediators, Mechanisms, and Pathways in Tissue Injury (Heinrich Taegtmeyer and Steven A. Atlas, Section Editors)


Sunitinib is a highly potent, multitargeted anticancer agent. However, there is growing clinical evidence that sunitinib induces cardiac dysfunction. Disruption of multiple signaling pathways, which are important in the maintenance of adult cardiac function, is likely to result in cardiovascular toxicity. Basic and translational evidence implicates a potential role for specific growth factor signaling pathways. This review discusses the relevant translational data from animal models of heart failure, focusing on three key pathways that are inhibited by sunitinib: AMP-activated protein kinase (AMPK), platelet-derived growth factor receptors (PDGFRs), and the vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. We hypothesize that disruption of these pathways by sunitinib results in cardiotoxicity, and present direct and indirect evidence to support the notion that sunitinib-induced cardiac dysfunction likely involves a variety of molecular mechanisms that are critical for cardiac homeostasis.


Sunitinib Heart failure Animal models Cardiac dysfunction Cardiotoxicity AMPK PDGFRs VEGFRs Molecular mechanisms 


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Center for Drug Evaluation and Research: Pharmacology Review. NDA No. 21-938/21-968. SU011248/Sutent. Available at Last accessed June 13, 2011.
  3. 3.
    Highlights of Prescribing Information: SUTENT® (sunitinib malate) capsules, oral. Available at Last accessed June 13, 2011.
  4. 4.
    Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007;13(18 Pt 1):5398–405.PubMedCrossRefGoogle Scholar
  6. 6.
    • Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010;106(1):21–34. This is a comprehensive review of the potential biologic mechanisms of current targeted cancer therapies. PubMedCrossRefGoogle Scholar
  7. 7.
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.PubMedCrossRefGoogle Scholar
  8. 8.
    Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS. Publish Date: August 9, 2006. Available at: Last accessed June 13, 2011.
  9. 9.
    Telli ML, Witteles RM, Fisher GA, et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19(9):1613–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20(9):1535–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500–8.PubMedCrossRefGoogle Scholar
  12. 12.
    • Kerkela R, Woulfe KC, Durand JB, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2009;2(1):15–25. This is one of the few studies defining the effects of administering sunitinib to animals. PubMedCrossRefGoogle Scholar
  13. 13.
    Will Y, Dykens JA, Nadanaciva S, et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008;106(1):153–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Hasinoff BB, Patel D, O’Hara KA. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol Pharmacol. 2008;74(6):1722–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Arad M, Seidman CE, Seidman JG. AMP-activated protein kinase in the heart: role during health and disease. Circ Res. 2007;100(4):474–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Gruber HE, Hoffer ME, McAllister DR, et al. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury. Circulation. 1989;80(5):1400–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Terai K, Hiramoto Y, Masaki M, et al. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol. 2005;25(21):9554–75.PubMedCrossRefGoogle Scholar
  18. 18.
    • Zhang P, Hu X, Xu X, et al. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008;52(5):918–24. This is a key article defining the role of AMPK in the cardiovascular system. PubMedCrossRefGoogle Scholar
  19. 19.
    Force T, Kerkela R. Cardiotoxicity of the new cancer therapeutics–mechanisms of, and approaches to, the problem. Drug Discov Today. 2008;13(17–18):778–84.PubMedCrossRefGoogle Scholar
  20. 20.
    Edelberg JM, Lee SH, Kaur M, et al. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation. 2002;105(5):608–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Hsieh PC, MacGillivray C, Gannon J, et al. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation. 2006;114(7):637–44.PubMedCrossRefGoogle Scholar
  22. 22.
    • Chintalgattu V, Ai D, Langley RR, et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest 2010;120(2):472–84. This is an outstanding study of the role of PDGFR-β in the maintenance of cardiac function. PubMedCrossRefGoogle Scholar
  23. 23.
    Hsieh PC, Davis ME, Lisowski LK, et al. Endothelial-cardiomyocyte interactions in cardiac development and repair. Annu Rev Physiol. 2006;68:51–66.PubMedCrossRefGoogle Scholar
  24. 24.
    Helotera H, Alitalo K. The VEGF family, the inside story. Cell. 2007;130(4):591–2.PubMedCrossRefGoogle Scholar
  25. 25.
    Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438(7070):932–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Abraham D, Hofbauer R, Schafer R, et al. Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ Res. 2000;87(8):644–7.PubMedGoogle Scholar
  27. 27.
    Izumiya Y, Shiojima I, Sato K, et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 2006;47(5):887–93.PubMedCrossRefGoogle Scholar
  28. 28.
    • Pepe M, Mamdani M, Zentilin L, et al. Intramyocardial VEGF-B167 gene delivery delays the progression towards congestive failure in dogs with pacing-induced dilated cardiomyopathy. Circ Res 2010;106(12):1893–903. This excellent study describes the effect of VEGF-B delivery on the nonischemic cardiomyopathy phenotype. PubMedCrossRefGoogle Scholar
  29. 29.
    Zhao Q, Ishibashi M, Hiasa K, et al. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension. 2004;44(3):264–70.PubMedCrossRefGoogle Scholar
  30. 30.
    Tammela T, Enholm B, Alitalo K, et al. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65(3):550–63.PubMedCrossRefGoogle Scholar
  31. 31.
    Belgore FM, Blann AD, Li-Saw-Hee FL, et al. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol. 2001;87(6):805–7. A9.PubMedCrossRefGoogle Scholar
  32. 32.
    Walsh K, Shiojima I. Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest. 2007;117(11):3176–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–58.PubMedGoogle Scholar
  34. 34.
    Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–83.PubMedCrossRefGoogle Scholar
  35. 35.
    Giordano FJ, Gerber HP, Williams SP, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A. 2001;98(10):5780–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Zentilin L, Puligadda U, Lionetti V, et al. Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction. FASEB J. 2010;24(5):1467–78.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Colin F. Greineder
    • 1
  • Sarah Kohnstamm
    • 2
  • Bonnie Ky
    • 3
  1. 1.Department of Pharmacology, Institute for Translational Medicine and Therapeutics, Department of Emergency MedicineUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  2. 2.Division of Cardiovascular MedicineUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  3. 3.Division of Cardiovascular Medicine, Center for Clinical Epidemiology and BiostatisticsUniversity of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations